About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Phase 1/2a Study of K-1728 in Advanced Solid Tumors

NCT07861932·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

KymaThera, Inc.

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Adults with advanced or metastatic solid tumors who are able to provide consent
Documented activating PIK3CA mutation
ECOG performance status 0 or 1
Adequate organ function

You may not be if

Active or untreated central nervous system disease
Clinical significant or uncontrolled cardiovascular disease
Significant or uncontrolled intercurrent illness
Pregnant or breastfeeding

The record

StatusNot yet recruiting

PhasePhase 1–2

Taking part110

StartedOct 2026

UpdatedOct 6, 2026

Conditions

Breast Neoplasms Solid Tumors PIK3CA Gene Mutation

Clareo Health | A Phase 1/2a Study of K-1728 in Advanced Solid Tumors